Clinical Trial Update: A Multicentre, Prospective, Single-arm, Non-interventional Regulatory Post-marketing Surveillance (rPMS) Study to Investigate the Safety and Effectiveness of Wegovy® (Semaglutide) in Patients With Obesity and Patients With Overweight in Routine Clinical Practice in Korea

View source ↗

Summary

A multicentre, prospective, single-arm, non-interventional post-marketing surveillance study evaluating the safety and effectiveness of Wegovy (semaglutide) in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight

Drugs mentioned

• WEGOVY (Semaglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Obesity and Overweight | Status: ENROLLING_BY_INVITATION